India has cleared Takeda’s Qdenga, the first dengue vaccine approved in the country. The Central Drugs Standard Control Organisation, or CDSCO, has authorised it for dengue prevention in people aged 4 to 60 years. The schedule has two 0.5 ml injections, given three months apart. This is a regulatory approval, not the start of a nationwide vaccination drive.
The announcement lands during the monsoon season, when dengue concern usually climbs across Indian cities. Qdenga targets all four dengue virus serotypes. Takeda expects to introduce it first through private healthcare facilities in the first half of 2027. Pricing, government procurement and any public vaccination plan have not yet been announced. PTI News also shared the approval on X.
Dengue vaccine development has been difficult because the disease is caused by four related virus serotypes. Protection after infection is strongest against the same serotype, while a later infection with another can still occur. That is why a tetravalent vaccine has drawn close attention from doctors and public-health teams.
What Exactly Has India Approved?
The official health ministry release describes Qdenga as a recombinant, live-attenuated tetravalent vaccine. In plain terms, it uses weakened forms of dengue viruses to train the body’s immune response without causing dengue disease. Its design uses dengue type 2 as the backbone, with surface-protein genes representing the other serotypes.
Takeda GmbH manufactures the vaccine in Germany, while Takeda Biopharmaceuticals India will import it. CDSCO said the approval followed an evaluation of quality, safety and efficacy. The evidence included a Phase III safety and immune-response study conducted among Indian participants aged 4 to 60 years.
The vaccine has WHO prequalification and approval in 42 countries, according to the government. More than 24 million doses have been distributed worldwide. The government said post-marketing surveillance in countries already using Qdenga found no significant safety concern. Indian safety monitoring will continue after launch. Approval also does not mean every eligible person needs the injection immediately.
Who Could Receive Qdenga In India?
India’s approved label covers children, teenagers and adults from their fourth birthday through age 60. Previous dengue infection is not required, and routine testing for an earlier infection is not expected before vaccination. Still, age eligibility alone does not settle whether the vaccine is suitable for one person. A doctor must review health history, medicines, allergies and current illness.
The WHO dengue vaccine guidance is narrower than India’s marketing authorisation. WHO recommends programme use mainly for children aged 6 to 16 years in places with high dengue transmission. It does not currently advise routine programme use below age six, and it urges caution in low-to-moderate transmission settings. A market licence and a public-health rollout answer separate questions.
Key eligibility points include:
- People aged 4 to 60 fall within India’s authorised range, subject to medical advice.
- A previous dengue infection is not compulsory, and routine pre-vaccination screening is not required.
- Pregnant or breastfeeding women should not receive this live vaccine under current medical guidance.
- People with immune deficiency or significant immunosuppressive treatment may not be suitable candidates.
- Vaccination should be postponed during a severe fever, while minor colds may not require delay.
Women planning pregnancy should avoid becoming pregnant for at least one month after vaccination. People living with symptomatic HIV, or HIV with impaired immune function, are also among those advised not to receive it. These checks are important because Qdenga is a live-attenuated vaccine, even though its viruses are weakened.
How Does Qdenga Work, And When Could It Arrive?
Qdenga is injected under the skin, usually in the upper arm. The second dose follows three months after the first. If that dose is delayed, WHO says the series does not need to restart. A booster schedule has not yet been established.
In Takeda’s late-stage trial, Qdenga showed 80.2% efficacy against confirmed dengue one year after the second dose. It showed 90.4% efficacy against dengue-related hospitalisation over 18 months. These are trial results, not a promise that every vaccinated person will avoid infection. Mosquito control, repellents, full-sleeve clothing, early testing and timely medical care remain necessary.
According to Reuters’ report on the Indian approval, Takeda plans a private-market launch in the first half of 2027. The company is also working with Hyderabad-based Biological E to support production of up to 50 million doses annually, while targeting wider global capacity by 2030.
Before any government campaign begins, authorities would need to decide target ages, high-burden districts, pricing, supply, surveillance and delivery channels. For now, Qdenga adds a new prevention option. It does not replace removing stagnant water or controlling Aedes mosquitoes around homes, schools and workplaces.
Frequently Asked Questions
What Is Qdenga?
Qdenga is Takeda’s live-attenuated vaccine designed to protect against all four known dengue virus serotypes.
Who Can Receive Qdenga In India?
India has authorised Qdenga for people aged four through sixty, subject to medical assessment first.
How Many Qdenga Doses Are Needed?
The course uses two 0.5 ml injections, with the second dose given three months later.
Does Prior Dengue Infection Matter?
Qdenga may be given without confirming an earlier dengue infection or conducting routine pre-vaccination screening.
When Could Qdenga Launch In India?
Takeda expects an Indian private-market launch during 2027’s first half, although pricing remains unannounced currently.
